43 results about "Ocular implant" patented technology

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include a plurality of implants, an external housing, and an introducer assembly. The external housing can provide access to an implant singulation actuator and an implant delivery actuator. The introducer assembly can comprise an auto- retracting introducer portion. The delivery apparatus can include an infinite activation mechanism / portion and / or a manual singulation mechanism / portion.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

This invention discloses an ocular implant and its delivery system, comprising: a flexible substrate; multiple nanowire arrays disposed on the flexible substrate; an elastic ring disposed along the circumferential edge of the flexible substrate, the elastic ring having elastic memory and capable of returning to its original shape before deformation after deformation; and two opposing openings disposed near the edge of the flexible substrate. The nanowire array of the ocular implant of this invention can be composed of multiple materials spliced ​​together, and materials with different efficacies and photosensitive wavelengths can be selected for splicing. Therefore, personalized ocular implants can be customized according to different patient conditions to achieve a better match with the patient's fundus condition. Furthermore, the folding and opening design of the ocular implant of this invention, as well as the self-expanding property of the elastic ring, enable it to be adapted to a delivery system for positioning and minimally invasive implantation.

An insertion device for an ocular implant for regulating intraocular pressure includes a cannula having an internal space for receiving at least a portion of an ocular implant having a stent and an implant opening for inserting the ocular implant; a handle configured to be connected to the cannula and held by a surgeon; and a holder configured to be coupled to the handle and including a receiving portion configured to receive the stent of the ocular implant. The ocular implant insertion device appropriately fixes the stent inserted into the tube of the ocular implant in a manner attached to the insertion device, thereby preventing problems such as the stent coming out of the tube, the implant being separated from the insertion device by the stent, or the stent obscuring the surgeon's field of vision during implant implantation surgery.

The present disclosure relates to methods of preparing biodegradable ocular implants containing edonentan, or a pharmaceutically acceptable salt thereof. The disclosure also relates to biodegradable ocular implants generally comprising a biodegradable polymer and edonentan, or a pharmaceutically acceptable salt thereof.

The invention relates to an extra-ocular implant (1) used to prevent worsening of pathological myopia, the implant comprising a support structure (10) produced in the form of an arm having, at a first end, anchoring means and a second end comprising a concavity (120), the implant (1) being characterized in that it further comprises a pouch (13) in which a compound suitable for inflating the pouch (13) is arranged, the pouch (13) being positioned at the second end of the arm so as to occupy the concavity (120), the implant (1) further comprising an attachment device (130) arranged on the pouch (13) for positioning against the posterior portion of the eye.

The disclosure relates to novel methods and materials particularly useful for ophthalmic applications and to methods for making and using the same. More particularly, the disclosure relates to relatively soft, optically transparent, foldable, high refractive index materials particularly suited for use in the production of intraocular lenses, contact lenses, and other ocular implants and to methods for manufacturing and implanting IOLs made therefrom.

Disclosed are ocular implants, ocular implant delivery systems, and methods of deploying an ocular implant. For example, the ocular implant can comprise a plurality of supporting frames and spines connecting the supporting frames. The ocular implant can comprise a distal supporting frame configured as an open trough having a trough nadir at a distal end. The trough nadir can be positioned radially outward of the spines. The ocular implant can also comprise a proximal portion comprising a pair of tool engagement ears curled laterally inward toward one another. A delivery system used to deploy the ocular implant can comprise a cannula comprising a distal portion having a proximal curved bend and a distal curved bend. The proximal curved bend can be bent in a different direction than the distal curved bend. The delivery system can also comprise a camera coupled to the cannula.

Described herein are devices configured to enable efficient grasping and delivery of film implants at open or minimally invasive surgical sites. An exemplary device includes: a tip portion configured to secure and protect a membrane implant device during treatment and installation to a surgical site; a handle portion configured to control the vacuum source; and a shaft portion configured to control vacuum and deliver vacuum from the vacuum source to the tip portion.

An ocular implant adapted to be disposed within Schlemm's canal of a human eye with a body extending along a curved longitudinal central axis in a curvature plane, a first strut on one side of the implant and a second strut on an opposite side of the implant, the circumferential extent of the first strut with respect to the plane of curvature being greater than the circumferential extent of the second strut with respect to the plane of curvature. The invention also includes methods of using the implant.

The present invention relates to an ocular implant comprising an amorphous solid dispersion (ASD) comprising a tyrosine kinase inhibitor (TKI), such as axitinib, and a polymer excipient. Further, the invention relates to methods of treatment using the ocular implant of the invention comprising the amorphous solid dispersion (ASD) in treating an ocular disease. According to the present invention, ocular diseases are treated by injecting an amorphous solid dispersion (ASD) or an ocular implant comprising the ASD into the eye, wherein the ocular implant releases the TKI. Moreover, the invention relates to processes for preparing an amorphous solid dispersion (ASD) and an ocular implant of the invention comprising an ASD.

The present disclosure relates to a biodegradable ocular implant comprising a biodegradable polymer containing a compound such as Edonentan, or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treatment of ocular diseases with the biodegradable ocular implant and methods of preparation of the same.

The present invention relates to polymer compositions, in particular to biocompatible cross-linkable polymer compositions, methods of preparing the same and their use in the preparation of ocular implants.

An ocular implant delivery system is provided with a number of features. In some embodiments, the delivery system comprises a rotation mechanism configured to rotate and orient a cannula of the system, and an advancement mechanism configured to advance and retract an ocular implant through the delivery system and into an eye of a patient. In some embodiments, the cannula is sized and configured to be inserted into Schlemm's canal of the eye. The ocular implant is configured to maintain its orientation within the delivery system as the cannula is rotated. In some embodiments, the ocular implant automatically disengages the delivery system when it is advanced beyond a distal tip of the delivery system. Methods of implanting an ocular implant are also provided.

An ocular implants, kits and deployment methods are disclosed. In one arrangement, an ocular implant has an elongate body configured to be deployable at a deployment position at which the body extends from the anterior chamber of an eye to the subconjunctival space of the eye. The body comprises a conduit structure defining a conduit for promoting flow of aqueous humour through the conduit from the anterior chamber to the subconjunctival space. The body comprises an anchoring structure configured to expand from a radially contracted state to a radially expanded state.

The present disclosure relates to the field of ocular implants suitable for sustained release of drugs (e.g., water-soluble drugs) and use of the ocular implants for treatment of ocular conditions, including glaucoma.

An ocular implant system including an ocular implant sized and shaped to be inserted at least partially into an eye; a carrier member with a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell. A guide sleeve removably attached within at least a first region of the central channel of the shell and defining a proximal port into the central channel that is accessible from the proximal end of the shell. An implant holder removably attached within at least a second region of the central channel of the shell adjacent to a distal end of the guide sleeve and having a pair of graspers adapted to releasably secure the implant at a distal end of the implant holder. Related devices, systems, and / or methods are described.

An ocular implant system is described herein in which an implant (200) is deployed in the posterior space of an eye - e.g., the suprachoroidal space or the subconjunctival space or the intrascleral space - through an access in the anterior chamber (160) for reducing intraocular pressure in the eye. The shunt device (200) is implanted using an implantation device that includes a hollow shaft (330) mounted on a fixed shaft (320). The shunt device (200) is located in the distal end of the hollow shaft (330) and adjacent to the distal end of the fixed shaft (320) at a location behind the distal end of the hollow shaft. Once the distal end of the hollow shaft (330) and the shunt device (200) are at the desired depth within the posterior space, the hollow shaft is withdrawn over the fixed shaft through the access in the anterior chamber (160) towards the proximal end of the fixed shaft, leaving the shunt device in the posterior space.

Disclosed herein are devices, systems, and methods configured to safely regulate aqueous outflow in a patient's eye while dynamically maintaining the normal range of intraocular pressure. An exemplary membrane implant includes a plurality of topographical features implemented on first and second surfaces of the implant. The topographical features include an interconnected channel network configured to direct aqueous in the patient's eye to flow through and across the surfaces of the membrane implant to reduce intraocular pressure. A plurality of control structures are implemented on one or more selected locations of the first and second surfaces to regulate the aqueous in the patient's eye.

This invention relates to a delivery device for bioabsorbable ocular drugs. Specifically, this invention relates to an ocular implant configured for implantation in the eye of a subject, comprising an elongated outer shell (54), an inner plug (210) containing hydrogel, and a drug reservoir comprising a drug (62), wherein the drug is configured to pass through at least a portion of the inner plug to control elution of the drug through the outer shell. The implant is made of a biodegradable material.

An ocular implant including a drug releasing element and having an inlet portion and a Schlemm's canal portion distal to the inlet portion, the inlet portion being disposed at a proximal end of the implant and sized and configured to be placed within an anterior chamber of a human eye, the Schlemm's canal portion being arranged and configured to be disposed within Schlemm's canal of the eye when the inlet portion is disposed in the anterior chamber.

Cyclosporine-eluting implants for treating a condition of the eye, and methods for their use, are disclosed herein. Also disclosed herein are methods for treating a condition of an eye of a subject. Also disclosed herein are methods of forming a system for treating a condition of an eye of a subject.

The present disclosure relates to the field of ocular implants suitable for sustained release of drugs (e.g., water-soluble drugs), and the use of ocular implants for the treatment of ocular diseases, including glaucoma.

An ocular implant is designed for controlled and sustained drug release to treat eye diseases such as age-related macular degeneration (AMD) and other degenerative conditions. The implant includes a body with an interior cavity, a first screen separating the cavity into inner and outer portions, and a second screen covering an opening in the body. A bioactive core containing a bioactive agent is housed in the cavity. The screens, with differing porosities, regulate the release rate of the agent. The implantation method involves making an incision near the target tissue, performing a blunt dissection, positioning the implant in the dissection tunnel with the tissue contact surface facing the target tissue, and securing it with sutures or tissue adhesive. This implant and method provide a minimally invasive, customizable solution for delivering therapeutic agents directly to the eye, improving treatment outcomes and patient compliance while reducing the need for frequent interventions.

An ocular implant (10) for delivering intraocular fluid from a site of intraocular fluid excess in a patient, the implant (10) comprising: a body (12) including one or more drainage channels (20), each having an outlet (24), the outlets being in fluid communication with a drainage site located away from the site of intraocular fluid excess; and an elongated tubular component (30) in fluid communication with the body (12), the component (30) having a first end portion (32) providing an inlet (38), a second end portion (34) providing an end (40), and so on. and a lumen extending between the inlet (38) and the end (40), wherein the inlet (38) is in fluid communication with the portion of the intraocular fluid excess, such that the intraocular fluid can flow through the inlet (38) and through the lumen to the end (40), and wherein the second end portion (34) includes one or more openings (42), each opening being in fluid communication with a corresponding drainage channel in one or more drainage channels (20) to allow the intraocular fluid to flow from the second end portion (34) to each outlet in the outlet (24).

The invention relates to a sustained release biodegradable ocular implant containing axitinib dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.